YOON CLINIC
Updated 22 August 2026

Korea GLP-1 price index

Every dose in won and dollars, next to the United States self-pay price for the same molecule. Including the doses where Korea is not the cheaper option.

What a course costs in Korea

Figures checked 16 August 2026

Pick a medication and dose to see the Korean price for a full course, and how it compares with the manufacturer self-pay programmes in the United States.

Korean prices include 10% VAT and cover a four-week supply per month. The first consultation is ₩50,000, applied toward treatment if you proceed the same day. Converted at 1 USD = 1,412 KRW. United States figures are manufacturer self-pay programme prices, not insured co-pays.

Tirzepatide, dose by dose

Mounjaro is the tirzepatide brand supplied in Korea. Zepbound is the brand licensed for weight management in the United States. The molecule is the same.

Tirzepatide

DoseKorea, YOON CLINICUS self-pay (Zepbound)
2.5 mg$312₩440,000$299Korea +$13
5.0 mg$390₩550,000$399Korea −$9
7.5 mg$467₩660,000$449Korea +$18
10 mg$545₩770,000$449Korea +$96
12.5 mg$701₩990,000$449Korea +$252
15 mg$779₩1,100,000$449Korea +$330

Semaglutide, dose by dose

Wegovy is sold under the same brand name in both countries.

Semaglutide

DoseKorea, YOON CLINICUS self-pay (Wegovy)
0.25 mg$390₩550,000$349Korea +$41
0.5 mg$390₩550,000$349Korea +$41
1.0 mg$425₩600,000$349Korea +$76
1.7 mg$467₩660,000$349Korea +$118
2.4 mg$503₩710,000$349Korea +$154

When Korea is worth it, and when it is not

Korea makes sense if

  • You cannot use a manufacturer self-pay programme, as these generally require a domestic prescription and residency
  • Your country has limited supply, long waits, or strict eligibility criteria
  • You are travelling to Korea anyway for work, family, or tourism
  • You want an examination, body composition analysis, and bloodwork in a single visit

Korea is probably not worth it if

  • You live in the United States, are on a higher dose, and qualify for the self-pay programmes, where the US figure is lower before you add a flight
  • You need continuous resupply and have no plan to return
  • You want the lowest price alone and do not need an examination
Two different American prices. The table above compares with the manufacturers’ self-pay programmes, which generally require a US prescription and residency. Those are far below the published list prices, which run to roughly $1,349 a month for Wegovy. Measured against list price Korea is less than half; measured against the self-pay programmes it is not. Which comparison applies depends on whether you can use those programmes.
Why we publish this. Clinics marketing to international patients usually show no prices at all, and often quote different figures in different languages. These are the figures used for Korean patients, and they are the same for everyone. Where another country is cheaper, this page says so.

Frequently asked

Do these prices include tax?

Yes. Korean figures include 10% VAT and cover a four-week supply. The first consultation is ₩50,000, applied toward treatment if you proceed the same day.

Are prices different for international patients?

No. These are the same figures used for Korean patients. There is no agency commission and no international-patient surcharge.

Why is Korea more expensive than the United States at higher doses?

American manufacturers cut their self-pay programme prices sharply in 2026, to $349 a month for Wegovy and $299 to $449 for Zepbound. Korean pricing is per pen strength and rises with the dose, so at higher doses the American self-pay figure is now lower. Against American list prices, which run to roughly $1,349 a month for Wegovy, Korea remains far cheaper.

Can I use my insurance?

Korean national health insurance does not cover weight management medication, and foreign insurance is not billed directly. An itemised English receipt is issued so you can claim with your own insurer if your policy covers overseas outpatient care.

How often are these prices updated?

Korean prices are set by the clinic and dated on every table. American self-pay figures are re-checked when the manufacturers change them, which in 2026 has been often. The check date is printed on this page.

How this page is maintained

Korean prices are set by the clinic and dated on every table across this site. United States self-pay figures come from the manufacturers' own published programme pricing and are re-checked when they change, which in 2026 has been often.

If a figure here is out of date, tell us and it will be corrected. Anyone is welcome to cite this page.

Sources: Eli Lilly published self-pay pricing for tirzepatide, Novo Nordisk NovoCare self-pay pricing for semaglutide, and the YOON CLINIC price list. Figures checked 16 August 2026. This page is price information, not medical advice, and does not indicate that any medication is appropriate for you.

Ask about your dose

Tell us what you take now and when you are in Seoul. We reply within one business day.